EA199900835A1 - Стабильная частица в жидких композициях - Google Patents

Стабильная частица в жидких композициях

Info

Publication number
EA199900835A1
EA199900835A1 EA199900835A EA199900835A EA199900835A1 EA 199900835 A1 EA199900835 A1 EA 199900835A1 EA 199900835 A EA199900835 A EA 199900835A EA 199900835 A EA199900835 A EA 199900835A EA 199900835 A1 EA199900835 A1 EA 199900835A1
Authority
EA
Eurasian Patent Office
Prior art keywords
microparticles
sugar glass
stable particle
liquid compositions
mannitol
Prior art date
Application number
EA199900835A
Other languages
English (en)
Other versions
EA001873B1 (ru
Inventor
Джаап Кампинга
Original Assignee
Квадрант Холдингс Кембридж Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10809442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199900835(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Квадрант Холдингс Кембридж Лимитед filed Critical Квадрант Холдингс Кембридж Лимитед
Publication of EA199900835A1 publication Critical patent/EA199900835A1/ru
Publication of EA001873B1 publication Critical patent/EA001873B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Стабильная частица в жидкой композиции, включающей дисперсные фазы микрочастиц, суспендируется в однородной фазе, которая представляет собой неводную жидкость, предпочтительно биосовместимую, в которой микрочастицы не растворяются. Микрочастицы содержат тонкоизмельченное сахарное "стекло" <1>, удерживающее, по крайней мере, один биомолекулярный продукт, биомолекулярный продукт в сахарном "стекле" либо находится в стабильном твердом растворе, либо сам по себе в суспензии в сахарном "стекле". Монодисперсная, состоящая из одного типа частиц суспензия микрочастиц может быть получена в неводной однородной жидкой фазе посредством включения в однородную фазу, по крайней мере, одного поверхностно-активного вещества, имеющего низкий или очень низкий гидрофильный липофильный баланс.Отчет о международном поиске был опубликован 1998.12.10.
EA199900835A 1997-03-18 1998-03-18 Стабильная частица в жидких композициях EA001873B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9705588.3A GB9705588D0 (en) 1997-03-18 1997-03-18 Stable particle in liquid formulations
PCT/GB1998/000817 WO1998041188A2 (en) 1997-03-18 1998-03-18 Stable particle in liquid formulations

Publications (2)

Publication Number Publication Date
EA199900835A1 true EA199900835A1 (ru) 2000-04-24
EA001873B1 EA001873B1 (ru) 2001-10-22

Family

ID=10809442

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900835A EA001873B1 (ru) 1997-03-18 1998-03-18 Стабильная частица в жидких композициях

Country Status (14)

Country Link
US (1) US6669963B1 (ru)
EP (1) EP1007000B1 (ru)
JP (1) JP2002504090A (ru)
CN (1) CN1256626A (ru)
AT (1) ATE325605T1 (ru)
AU (1) AU722627B2 (ru)
BR (1) BR9808920A (ru)
CA (1) CA2293682C (ru)
DE (1) DE69834495T2 (ru)
EA (1) EA001873B1 (ru)
GB (1) GB9705588D0 (ru)
NO (1) NO994508L (ru)
NZ (1) NZ337666A (ru)
WO (1) WO1998041188A2 (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0782398A1 (en) 1994-09-22 1997-07-09 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
AU2945199A (en) * 1998-03-18 1999-10-11 Ronai, Peter Amorphous glasses for stabilising sensitive products
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
DE19943491B4 (de) * 1999-09-10 2010-04-01 Südzucker AG Mannheim/Ochsenfurt Verbesserte Komprimate
AU2046101A (en) * 1999-11-22 2001-06-04 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
GB0024271D0 (en) * 2000-09-25 2000-11-15 Colaco Camilo Improved methods and compositions for pulmonary delivery of actives
ATE450253T1 (de) * 2000-10-13 2009-12-15 Cambridge Biostability Ltd Pharmazeutische flüssige suspensionen
ES2337252T3 (es) * 2000-10-13 2010-04-22 Nova Bio-Pharma Technologies Limited Suspensiones liquidas farmaceuticas.
WO2002032398A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for drug delivery
US7153472B1 (en) 2000-11-22 2006-12-26 Quadrant Drug Delivery Limited Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
US6623762B2 (en) * 2001-02-16 2003-09-23 Cambridge Biostability Ltd. Composition and method for controlled release injections
FR2825276B1 (fr) * 2001-05-31 2004-11-26 Seppic Sa Adujvant d'immunite sous forme solide et vaccin le contenant
JP4169344B2 (ja) * 2001-07-02 2008-10-22 旭化成ファーマ株式会社 アルカリホスファターゼ安定化方法
KR100927764B1 (ko) * 2001-08-10 2009-11-20 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 트레할로오스 또는 말티톨과 금속 이온 화합물과의 회합물(會合物)
GB2379390B (en) 2001-09-11 2005-01-26 Caretek Medical Ltd A novel drug delivery technology
MXPA04005865A (es) 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
ZA200602347B (en) * 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
US20060142630A1 (en) * 2004-12-29 2006-06-29 Attila Meretei Systems and methods for treating a thrombus in a blood vessel
US7515971B1 (en) * 2005-09-09 2009-04-07 Pacesetter, Inc. Left atrial pressure sensor lead
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
US8946200B2 (en) 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
DE102006056790B3 (de) * 2006-12-01 2008-01-17 IfP Privates Institut für Produktqualität GmbH Laboreinmalartikel für Analyse und Diagnosik
EP1930396B1 (de) * 2006-12-04 2011-07-06 Merck Patent GmbH Furochromanderivate
WO2008092084A2 (en) * 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
UA97286C2 (ru) * 2007-07-31 2012-01-25 Оцука Фармасьютикал Ко., Лтд. Способ изготовления суспензии арипипразола и лиофилизированного состава
WO2009108689A1 (en) * 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
US8404850B2 (en) 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US8722706B2 (en) 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
WO2011007327A2 (en) * 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension for therapeutic use and device for delivering said suspension
US8293299B2 (en) 2009-09-11 2012-10-23 Kraft Foods Global Brands Llc Containers and methods for dispensing multiple doses of a concentrated liquid, and shelf stable Concentrated liquids
CN102115737B (zh) * 2009-12-31 2015-06-03 深圳迈瑞生物医疗电子股份有限公司 稳定碱性磷酸酶或其标记物的试剂和方法
US9028873B2 (en) 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
CN102269762B (zh) 2010-06-04 2014-12-10 深圳迈瑞生物医疗电子股份有限公司 结合物的制备方法及相关试剂盒
CN102269761A (zh) 2010-06-04 2011-12-07 深圳迈瑞生物医疗电子股份有限公司 一种碱性磷酸酶结合物的合成工艺
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
BR112014005499B1 (pt) 2011-09-09 2020-09-15 Kraft Foods Group Brands Llc Concentrado líquido de bebida de café infundido e seu método de preparação
KR102196009B1 (ko) 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
US11013248B2 (en) 2012-05-25 2021-05-25 Kraft Foods Group Brands Llc Shelf stable, concentrated, liquid flavorings and methods of preparing beverages with the concentrated liquid flavorings
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
NZ728172A (en) 2014-07-03 2023-06-30 Kraft Foods Group Brands Llc Low water coffee and tea beverage concentrates and methods for making the same
CN111558046A (zh) * 2020-05-27 2020-08-21 华润昂德生物药业有限公司 海藻糖在制备重组人促红素液体制剂中的应用及重组人促红素液体制剂、制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031255A (en) * 1975-07-03 1977-06-21 General Foods Corporation Fixing acetaldehyde in sucrose
US3970765A (en) * 1975-07-03 1976-07-20 General Foods Corporation Method for producing sucrose fixed volatile flavors
GB1490814A (en) * 1975-07-22 1977-11-02 Cadbury Ltd Heat-resistant chocolate product and method of manufacturing same
JPS562908A (en) * 1979-06-20 1981-01-13 Nikken Kagaku Kk Preparation of stable live bacterial pharmaceutical remedy
DE3484584D1 (de) * 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
WO1989003671A1 (en) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Sustained-release preparation
US5250429A (en) * 1991-09-20 1993-10-05 Pharmacia P-L Biochemicals Inc. Glassified restriction enzymes
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
EP1138337A3 (en) * 1994-08-04 2003-03-26 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5593824A (en) * 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
IL122482A (en) 1995-06-07 1999-10-28 Quadrant Holdings Cambridge Methods for stably incorporating substances within dry foamed glass matrices and compositions obtained thereby
US5958455A (en) 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US5762961A (en) 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5766520A (en) 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation

Also Published As

Publication number Publication date
NO994508D0 (no) 1999-09-17
WO1998041188A2 (en) 1998-09-24
DE69834495T2 (de) 2006-09-07
US6669963B1 (en) 2003-12-30
AU6510198A (en) 1998-10-12
NZ337666A (en) 2001-04-27
JP2002504090A (ja) 2002-02-05
CN1256626A (zh) 2000-06-14
ATE325605T1 (de) 2006-06-15
AU722627B2 (en) 2000-08-10
CA2293682C (en) 2007-01-16
CA2293682A1 (en) 1998-09-24
WO1998041188A3 (en) 1998-12-10
EP1007000A2 (en) 2000-06-14
GB9705588D0 (en) 1997-05-07
BR9808920A (pt) 2000-08-01
EA001873B1 (ru) 2001-10-22
EP1007000B1 (en) 2006-05-10
NO994508L (no) 1999-11-17
DE69834495D1 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
EA199900835A1 (ru) Стабильная частица в жидких композициях
NZ336594A (en) Formulation for inhalation which includes a carrier (lactose, glucose, raffinose, melezitose, lactitol, trehalose, sucrose, mannitol or starch
HUT59005A (en) Process for producing transdermal pharmaceutical preparations containing 2-amino-6-(propyl-amino)-4,5,6,7-tetrahydro-benzothiazole
TW224428B (ru)
ZA9811799B (en) Solid galenic form of the controlled release tablet type for the instant and then prolonged release of one or more active substances
CA2024291A1 (en) Dosage device and preparation and use thereof
PT1137400E (pt) Composicoes contendo um peptideo e um acido polilactico-glicolico apropriado para preparar implantes subscutaneos com um periodo de libertacao prolongado
MY118835A (en) Sustained release compositions and the process for their preparation
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
PT98272A (pt) Processo para a preparacao de uma composicao farmaceutica para suspensao rapida em agua
IT1246188B (it) Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita&#39; di dissoluzione della sostanza attiva e composizioni ottenute.
HUP0203935A3 (en) Sulfonamides and derivatives thereof that modulate the activity of endothelin, pharmaceutical compositions containing them and their use
NZ336593A (en) Formulation comprising finely divided formoterol and a carrier (lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol or starch
IT8720129A0 (it) Composizioni farmaceutiche sottoforma di sospensioni stabili di sucralfato esenti da agenti sospendenti.
HUP0500127A2 (en) Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
AU2002327097A1 (en) Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
BR0008713A (pt) Processos para preparar formulações ecomposições farmacêuticas orais com ecb
MX9606391A (es) Preparacion farmaceutica con una sustancia activa hidrofobica y un sistema efervecente, y proceso para preparar la misma.
AU8229998A (en) Modified glycosides, compositions comprised thereof and methods of use thereof
NZ336595A (en) Formulation for inhalation comprising finely divided terbutaline sulphate and a carrier (lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol or starch)
NO965483L (no) Dinukleosid-5&#39;,5&#39;-pyrofosfater
IL93719A0 (en) (5(6)(benzisoxa-benzisothia-or indazol-3-yl)-1h-benzimidazol-2-yl)carbamates,their preparation and pharmaceutical compositions containing them
CA2314112A1 (en) A method for making a pharmaceutical formulation
HU908294D0 (en) Fungicide preparations containing pyridyl-cyclopropane as active agent and process for the preparation of the active agents
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU